Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly raised RMB59 million (USD8.7 million) in a Series A + financing round. The round was led by Utrust Fund and Baidu Venture, among others. The proceeds will support the research and development of off-the-shelf universal DNT cell therapies.
Funding Details
The funds will be used for a confirmatory Phase II clinical study for RC1012 in relapsed and refractory acute myeloid leukemia (r/rAML), another clinical filing for RC1012, and an IND filing for the CD19-CAR-DNT cell therapy. They will also support pre-clinical studies for new product pipelines, construction of the headquarters in Zhongshan Life Science Park, Guangdong Province, Shanghai R & D Center, and Shaoxing Keqiao New Preparation Center, as well as expansion of the R & D team.
Technology and Clinical Progress
The DNT cell therapies developed by Wyze Bio are derived from peripheral blood mononuclear cells of healthy donors. These therapies have shown significant specific killing effects on AML and other tumor cells. Clinical studies have demonstrated that allogeneic DNT cells do not cause graft-versus-host disease or other serious adverse reactions after infusion into patients, exhibiting good safety and significant durable anti-tumor activity. In November 2020, the company’s RC1012 fresh preparation received approval for a Phase I clinical study in China, marking the first universal immunotherapy to be approved for trials in the country. This month, the category of “fresh preparation” was approved to be changed to “frozen preparation” by the Center for Drug Evaluation (CDE).-Fineline Info & Tech
